Tabula Rasa HealthCare (NASDAQ:TRHC) Downgraded to Sell at BidaskClub

BidaskClub downgraded shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a hold rating to a sell rating in a report issued on Wednesday, BidAskClub reports.

Other research analysts have also issued research reports about the stock. ValuEngine lowered shares of Tabula Rasa HealthCare from a strong-buy rating to a buy rating in a research report on Wednesday. Stifel Nicolaus raised shares of Tabula Rasa HealthCare from a hold rating to a buy rating and boosted their target price for the stock from $50.00 to $75.00 in a research report on Friday, August 30th. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a buy rating to a hold rating in a research report on Saturday, November 9th. Cantor Fitzgerald cut their target price on shares of Tabula Rasa HealthCare from $99.00 to $85.00 and set an overweight rating for the company in a research report on Friday, November 8th. Finally, Piper Jaffray Companies cut their target price on shares of Tabula Rasa HealthCare from $78.00 to $66.00 and set an overweight rating for the company in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $71.54.

Shares of Tabula Rasa HealthCare stock traded up $1.09 on Wednesday, hitting $42.15. 322,300 shares of the company traded hands, compared to its average volume of 341,000. The company has a market cap of $911.74 million, a PE ratio of 123.97 and a beta of 1.62. The company has a quick ratio of 2.13, a current ratio of 2.22 and a debt-to-equity ratio of 1.32. Tabula Rasa HealthCare has a 12-month low of $40.06 and a 12-month high of $78.20. The company has a 50-day moving average price of $50.47 and a 200 day moving average price of $52.62.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its earnings results on Thursday, November 7th. The company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $74.27 million during the quarter, compared to analyst estimates of $75.37 million. Tabula Rasa HealthCare had a negative net margin of 13.46% and a positive return on equity of 0.50%. Equities research analysts anticipate that Tabula Rasa HealthCare will post -0.23 EPS for the current year.

In other news, CFO Brian W. Adams sold 2,000 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the transaction, the chief financial officer now owns 198,037 shares in the company, valued at approximately $11,882,220. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $56.05, for a total transaction of $448,400.00. In the last 90 days, insiders have sold 72,000 shares of company stock worth $4,032,090. Insiders own 11.80% of the company’s stock.

Several large investors have recently bought and sold shares of TRHC. First Trust Advisors LP increased its holdings in shares of Tabula Rasa HealthCare by 722.5% during the 2nd quarter. First Trust Advisors LP now owns 418,301 shares of the company’s stock worth $20,886,000 after purchasing an additional 367,445 shares during the period. Janus Henderson Group PLC bought a new stake in Tabula Rasa HealthCare in the second quarter valued at about $17,074,000. Intrinsic Edge Capital Management LLC increased its stake in Tabula Rasa HealthCare by 173.3% in the second quarter. Intrinsic Edge Capital Management LLC now owns 358,673 shares of the company’s stock valued at $17,909,000 after acquiring an additional 227,453 shares during the period. Brown Advisory Inc. bought a new stake in Tabula Rasa HealthCare in the second quarter valued at about $11,133,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Tabula Rasa HealthCare by 18.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,315,216 shares of the company’s stock valued at $65,669,000 after acquiring an additional 202,683 shares during the period. Institutional investors own 99.58% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Recommended Story: What is diluted earnings per share (Diluted EPS)?

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.